David C Polidori

List of Publications by Year
in descending order

37 papers	3,147 citations	236925 25 h-index	345221 36 g-index
38 all docs	38 docs citations	38 times ranked	3721 citing authors

#	Article	IF	Citations
1	Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: A crossâ€sectional and longitudinal study from the <scp>Y</scp>ale <scp>P</scp>ediatric <scp>NAFLD</scp> cohort. Diabetes, Obesity and Metabolism, 2020, 22, 1628-1638.	4.4	26
2	Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics. Journal of Clinical Investigation, 2020, 130, 3305-3314.	8.2	45
3	Lower Insulin Clearance Parallels a Reduced Insulin Sensitivity in Obese Youths and Is Associated With a Decline in Î²-Cell Function Over Time. Diabetes, 2019, 68, 2074-2084.	0.6	30
4	Response to Letter to the Editor: â€œHepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Contentâ€• Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5251-5252.	3.6	0
5	Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1855-1865.	3.6	45
6	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 812-821.	4.4	117
7	Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 676-687.	2.5	24
8	Intraâ€•and interâ€subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose coâ€transporter 2 inhibitor canagliflozin. Diabetes, Obesity and Metabolism, 2018, 20, 1321-1326.	4.4	47
9	Quantitative path to deep phenotyping: Possible importance of reduced hepatic insulin degradation to type 2 diabetes mellitus pathogenesis. Journal of Diabetes, 2018, 10, 778-783.	1.8	3
10	Dissection of hepatic versus extraâ€hepatic insulin clearance: Ethnic differences in childhood. Diabetes, Obesity and Metabolism, 2018, 20, 2869-2875.	4.4	20
11	Hepatic but Not Extrahepatic Insulin Clearance Is Lower in African American Than in European American Women. Diabetes, 2017, 66, 2564-2570.	0.6	60
12	How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake. Obesity, 2016, 24, 2289-2295.	3.0	145
13	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 44-51.	3.6	212
14	Hepatic and Extrahepatic Insulin Clearance Are Differentially Regulated: Results From a Novel Model-Based Analysis of Intravenous Glucose Tolerance Data. Diabetes, 2016, 65, 1556-1564.	0.6	80
15	Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. Clinical Therapeutics, 2016, 38, 89-98.e1.	2.5	12
16	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes and Metabolism, 2016, 42, 25-32.	2.9	107
17	Canagliflozin: a sodium glucose coâ€transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences, 2015, 1358, 28-43.	3.8	75
18	Effect of canagliflozin, a sodium glucose coâ€transporter 2 inhibitor, on Câ€peptide kinetics. Clinical Pharmacology in Drug Development, 2015, 4, 12-17.	1.6	6

#	Article	IF	Citations
19	Clinical Pharmacokinetic, Pharmacodynamic, and Drugâ€“Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clinical Pharmacokinetics, 2015, 54, 1027-1041.	3.5	83
20	Determination of the Renal Threshold for Glucose Excretion in Familial Renal Glucosuria. Nephron, 2015, 129, 300-304.	1.8	12
21	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Clinical Therapeutics, 2015, 37, 1483-1492.e1.	2.5	20
22	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia, 2015, 58, 1183-1187.	6.3	118
23	Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management, 2015, 5, 183-201.	0.5	9
24	Efficacy and Safety of Canagliflozin, a Sodiumâ€“Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care, 2015, 38, 2258-2265.	8.6	235
25	Sodiumâ€“Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport. Diabetes Care, 2015, 38, 2344-2353.	8.6	186
26	Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE, 2014, 9, e105638.	2.5	53
27	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism: Clinical and Experimental, 2014, 63, 1296-1303.	3.4	43
28	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia, 2014, 57, 891-901.	6.3	96
29	Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants. Clinical Therapeutics, 2014, 36, 698-710.	2.5	46
30	Effects of Meal Size on the Release of GLP-1 and PYY After Roux-en-Y Gastric Bypass Surgery in Obese Subjects With or Without Type 2 Diabetes. Obesity Surgery, 2014, 24, 1969-1974.	2.1	22
31	Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method. Theoretical Biology and Medical Modelling, 2014, 11, 33.	2.1	11
32	Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Coâ€Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2013, 53, 601-610.	2.0	179
33	Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E867-E871.	3.6	77
34	Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion. Diabetes Care, 2013, 36, 2154-2161.	8.6	234
35	Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes. Diabetes Care, 2012, 35, 1232-1238.	8.6	372
36	Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE, 2012, 7, e30555.	2.5	193

#	Article	IF	Citations
37	Roux-en-Y Gastric Bypass Corrects Hyperinsulinemia Implications for the Remission of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2525-2531.	3.6	104